Bispecific Antibody Provides Durable Remission in Myeloma

REGN5459, designed to deplete plasma cells while mitigating the cytokine release syndrome, demonstrated deep and durable clinical responses in heavily pretreated relapsed/refractory myeloma.

Related Keywords

Dana Farber Cancer Institute ,Massachusetts ,United States ,Orlando ,Florida ,Boston ,American ,Attaya Suvannasankha ,Kenneth Anderson ,Amgen ,Indiana University Simon Cancer Center ,Pfizer ,Regeneron Pharmaceuticals ,American Association For Cancer Research ,Lebow Institute For Myeloma Therapeutics ,Jerome Lipper Multiple Myeloma Center ,Drug Administration ,American Association ,Cancer Research ,Annual Meeting ,Earlier Lines ,Medscape Medical ,Lebow Institute ,Myeloma Therapeutics ,Raqia Next ,Multiple Myeloma ,Myeloma ,Plasma Cell Myeloma ,Remission ,Cancer ,Alignant Neoplasia ,Arcinoma ,Biologic Therapy ,Cytokines ,Plasma ,Otolaryngology ,Nt Ears ,Nose ,Throat ,Toxicology ,Chimeric Antigen Receptort Cell Therapy ,Chimeric Antigen Receptors ,Himeric Immunoreceptors ,Himerict Cell Receptors ,Rtificialt Cell Receptors ,Ar T ,Antigens ,Hands ,Refractory ,Residual Disease ,Adverse Effects , ,